Good morning :)
$
₹
Elanco Animal Health

Elanco Animal Health

ELAN

NYSE
Asset Logo

Elanco Animal Health

ELAN

NYSE
$25.718.61% (+2.03)
$
₹
$25.718.61% (+2.03)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Large Cap

With a market cap of $12.6B the stock is ranked 844

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.86
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.42
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

4.04
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-3.96%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 16 analysts reports

Buy
13 analysts
Hold
3 analysts
Sell
0 analyst

Price Upside

+17.45%

Earnings Growth

+19.01%

Rev. Growth

+8.8%

See Detailed Forecast

Company Profile

Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.74
45.74
1Y Return
44.64%
44.64%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.93
41.93
1Y Return
48.67%
48.67%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
151.87
151.87
1Y Return
71.05%
71.05%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
31.48
31.48
1Y Return
28.42%
28.42%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.73
26.73
1Y Return
10.56%
10.56%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 17.45% growth, versus a trailing 3-year CAGR of 40.10%.

2026
Current$25.74Baseline
Analyst Target - 1 year
Target$30.23+17.45%

All values in $

202220232024202520262027$16.49$22.08$27.66Target+17.45%
2026
Current$25.74Baseline
Analyst Target - 1 year
Target$30.23+17.45%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 8.80% growth, versus a trailing 3-year CAGR of 2.25%.

2025
Current$4.71Baseline
Forecast for Dec 2026
High$5.20+10.36%
Average$5.13+8.8%
Low$5.10+8.21%

All values in $ Billion

2021202220232024202520264.764.414.414.434.71Low+8.21%Average+8.8%High+10.36%
2025
Current$4.71Baseline
Forecast for Dec 2026
High$5.20+10.36%
Average$5.13+8.8%
Low$5.10+8.21%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 19.01% growth, versus a trailing 3-year CAGR of -5.06%.

2025
Current$0.95Baseline
Forecast for Dec 2026
High$1.15+21.05%
Average$1.13+19.01%
Low$1.1+15.79%

All values in $

2021202220232024202520261.051.110.890.910.95Low+15.79%Average+19.01%High+21.05%
2025
Current$0.95Baseline
Forecast for Dec 2026
High$1.15+21.05%
Average$1.13+19.01%
Low$1.1+15.79%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

1.1
-0
1.1
-0.2
1.3
0
1.3
0
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.201.181.031.021.191.241.131.141.371.36
Net Income0.03-0.050.36-00.060.01-0.03-0.270.050.05
Net Profit Margin2.65%-4.22%35.33%-0.78%5.61%0.88%-2.99%-24.12%4.15%3.94%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Elanco Animal Health -1.864.04
Eli Lilly and Company45.7431.171.32
Johnson & Johnson41.937.852.99
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ELAN with any stock or ETF
Compare ELAN with any stock or ETF
Comparing from
ELAN
LLY
JNJ
Loading...

Frequently asked questions

  1. Elanco Animal Health (ELAN) share price today is $25.71 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $26.25 and a day low of $23.91.

  2. Elanco Animal Health stock trades on NYSE under the ticker symbol ELAN.

  3. Elanco Animal Health's market capitalization is $12.64B as of November 7, 2026 at 2:29 AM IST.

  4. Elanco Animal Health's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Elanco Animal Health's price-to-book (P/B) ratio is 1.86 as of November 6, 2026.

  6. Yes, You can buy Elanco Animal Health shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Elanco Animal Health shares in three steps: 1. Search Elanco Animal Health on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Elanco Animal Health trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Elanco Animal Health (ELAN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3888 shares at the current price of $25.71.

Loading...